2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12A.12 Lazertinib as Second-Line or Greater Treatment is More Effective in Patients who Showed Extended Response to Prior TKI in Advanced NSCLC

EP.12A.12 Lazertinib as Second-Line or Greater Treatment is More Effective in Patients who Showed Extended Response to Prior TKI in Advanced NSCLC

Back to course

Pdf Summary

The study, conducted by Chang Dong Yeo, evaluates the real-world efficacy and safety of lazertinib, an oral third-generation EGFR-TKI, as a second-line or greater treatment for advanced non-small cell lung cancer (NSCLC). Lazertinib specifically targets the EGFR T790M mutation and activating mutations Ex19del and L858R. The research involved a multicenter retrospective analysis at seven university hospitals affiliated with the Catholic Medical Center in Korea, utilizing a clinical data warehouse for information extraction.<br /><br />The study assessed 48 patients, predominantly female (75%) and diagnosed with adenocarcinoma (95.8%). All patients presented with an EGFR mutation at diagnosis, 56.3% had the exon 19 deletion, 41.7% had the L858R mutation, and 2% had the exon 18 mutation. The median progression-free survival (PFS) observed was 15.4 months, with PFS rates at 6, 12, and 18 months being 79.1%, 53.6%, and 27.3%, respectively. Significant differences in PFS were observed when analyzed based on prior TKI duration (p=0.013 and p=0.010 at 6 and 9 months, respectively). Multivariate analysis indicated that prior TKI duration and ECOG score were statistically significant factors influencing PFS (p=0.026 and p=0.049, respectively), with the ECOG score also showing significance for overall survival (OS) (p=0.006).<br /><br />Adverse events (AEs) were reported in 70.8% of the patients, the most common being skin reaction (29.8%), diarrhea (21.3%), and peripheral neuropathy (20.8%).<br /><br />In conclusion, the study suggests that lazertinib is effective and has a tolerable safety profile in second or greater line treatments for NSCLC. Although the results are promising, further data is necessary to identify potential prognostic markers related to patient outcomes.

Asset Subtitle

Chang Dong Yeo

Meta Tag

Speaker Chang Dong Yeo

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

lazertinib

EGFR-TKI

NSCLC

EGFR mutation

progression-free survival

adenocarcinoma

adverse events

prognostic markers

retrospective analysis

Catholic Medical Center